Mylan Signs Collaboration Agreement With Biocon

Published: 29-Jun-2009

Mylan and Biocon are likely to share development, capital and other costs to bring products to market

Mylan has collaborated with Biocon on the development, manufacturing, supply and commercialization of multiple, high-value generic biologic compounds for the global marketplace.

As part of the collaboration, Mylan and Biocon would share development, capital and certain other costs to bring products to market. Mylan would have exclusive commercialization rights in the US, Canada, Japan, Australia, New Zealand and in the EU and European Free Trade Association countries, through a profit sharing arrangement with Biocon. Mylan would have co-exclusive commercialization rights with Biocon in all other markets. All other financial terms and product details remain confidential.

Dr. Kiran Mazumdar-Shaw, Chairman and Managing Director, Biocon, said: Biocon is extremely pleased to have found a partner as strong as Mylan to accelerate our work in generic biologics, especially with monoclonal antibodies, and take it to the next level around the world, especially in regulated markets.

I am confident that our shared vision for the sector, complementary skills, mutual respect and work ethic will make this collaboration a remarkable success while bringing additional value to Biocon and its shareholders. Monoclonal antibodies are emerging as the most dominant class in biologics. Through this partnership we hope to deliver high quality, affordable biogeneric antibodies and biologics, thereby addressing a critical need to lower spiraling healthcare costs in both the developed and emerging economies, she added.

Tell your friend about this article